This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
by Zacks Equity Research
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
by Zacks Equity Research
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
by Zacks Equity Research
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
by Zacks Equity Research
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
by Zacks Equity Research
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
by Zacks Equity Research
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.